How to Best Utilize the New CTMSS Recommended OCD Coverage Policy
The webinar will review the key elements contained in the recommended coverage policy for Transcranial Magnetic Stimulation for the treatment of patients with treatment-resistant obsessive-compulsive disorder. Indication for coverage, patient selection criteria including limitations, and utilization guidelines and recommended TMS protocol will also be reviewed. At the end of the webinar, providers will have a better understanding of how to utilize the coverage policy to advocate for their OCD patients.
- Understand the content in the policy;
- Understand the recommended patient selection criteria;
- Understand the clinical evidence to support the policy;
- Understand how to use the policy as a part of your initial payer coverage requests, calls and/or meetings with medical directors and peer to peer conversations and appeals.
Date: March 17, 2021
Time: 5:00 pm PDT / 8:00 pm EDT
*This event is FREE for CTMSS Members Only.
Carlene MacMillan, MD
Carlene MacMillan, MD is the co-Founder and CEO of Brooklyn Minds Psychiatry, a multidisciplinary team-based multi-site practice in the NYC Region. She is a graduate of Harvard College and Harvard Medical School and completed her adult psychiatry residency and child and adolescent fellowship at Massachusetts General Hospital/McLean Hospital. In her work at Brooklyn Minds, she has built a robust deep TMS program over the past 4 years. Brooklyn Minds was one of the first practices in the country to offer deep TMS for OCD upon FDA clearance. As a member of the CTMSS Insurance Committee, she focuses primarily on advocating for appropriate OCD coverage policies as her team at Brooklyn Minds has been at the forefront of obtaining insurance coverage from commercial and Medicaid payers. She is a co-author on the post-marketing paper on dTMS for OCD published earlier this year.
Scott Blackman, CMBS
Scott Blackman has 30 years of medical device and pharmaceutical industry experience working in the areas of sales, marketing, and reimbursement. Scott is currently the Director of Market Access for BrainsWay where he leads the reimbursement efforts for Deep transcranial magnetic stimulation (Deep TMS) technology. Prior to BrainsWay, Scott was the National Director for payer policy and reimbursement for Medical Technology Partners, Inc. (MTP), a well-known and respected medical device reimbursement consulting company. Scott played an important role at MTP by leading payer coverage acceleration and market access tactics and strategies for a number of medical device companies over the past nine years including neurostimulation technologies. Before joining MTP, he held market access and sales professional roles at Olympus, Cyberonics (now known as LivaNova), and at his first healthcare company, Pfizer. During Scott’s 14-year career at Pfizer, he promoted their CNS therapeutic products for conditions including depression, obsessive-compulsive disorder, bipolar disorder, anxiety disorders, schizophrenia, and Alzheimer’s disease. Thus, he is very acquainted with the TMS industry and the challenges our customers face in the mental health market. Before his healthcare career, Scott served as a captain in the United States Marine Corps for nine years and is a graduate of the University of South Carolina.
Aron Tendler, MD
Dr. Tendler is board certified in general psychiatry, obesity medicine and sleep medicine. He sees patients thirty hours a week, and is engaged in clinical research and education on neuromodulation as the Chief Medical Officer for BrainsWay thirty hours a week.